Franklin Resources Inc. Has $6.25 Million Stock Holdings in Sanofi (NASDAQ:SNY)

Franklin Resources Inc. reduced its position in shares of Sanofi (NASDAQ:SNYFree Report) by 5.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 125,587 shares of the company’s stock after selling 7,683 shares during the quarter. Franklin Resources Inc.’s holdings in Sanofi were worth $6,245,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brandes Investment Partners LP grew its holdings in shares of Sanofi by 64.6% during the fourth quarter. Brandes Investment Partners LP now owns 1,770,572 shares of the company’s stock valued at $88,051,000 after buying an additional 694,957 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after purchasing an additional 651,756 shares during the last quarter. Natixis Advisors L.P. lifted its holdings in shares of Sanofi by 15.9% in the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock valued at $135,618,000 after purchasing an additional 346,563 shares in the last quarter. Morgan Stanley boosted its position in shares of Sanofi by 4.6% during the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after buying an additional 323,968 shares during the last quarter. Finally, Clough Capital Partners L P bought a new stake in Sanofi during the third quarter worth $14,719,000. Institutional investors own 10.04% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of a number of analyst reports. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Get Our Latest Stock Report on Sanofi

Sanofi Stock Up 2.5 %

Shares of NASDAQ:SNY opened at $49.03 on Friday. The company has a market capitalization of $124.04 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.49 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. The business has a fifty day moving average price of $48.30 and a two-hundred day moving average price of $48.32. Sanofi has a 1 year low of $42.63 and a 1 year high of $55.72.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.96. The firm had revenue of $11.36 billion during the quarter, compared to the consensus estimate of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Analysts forecast that Sanofi will post 4.13 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be paid a $1.478 dividend. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. This is an increase from Sanofi’s previous annual dividend of $1.38. Sanofi’s dividend payout ratio is 74.37%.

About Sanofi

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Further Reading

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.